Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis by Ganesan, A. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/82942  
 
Anand N. Ganesan, Nicholas J. Shipp, Anthony G. Brooks, Pawel Kuklik, Dennis H. Lau, Han S. Lim, 
Thomas Sullivan, Kurt C. Roberts‐Thomson and Prashanthan Sanders 
Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-
analysis 
Journal of the American Heart Association, 2013; 2(2):e004549-1-e004549-14 
© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley‐Blackwell. 
This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial 
License, which permits use, distribution and reproduction in any medium, provided the original work 
is properly cited and is not used for commercial purposes. 
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Background-—In the past decade, catheter ablation has become an established therapy for symptomatic atrial ﬁbrillation (AF).
Until very recently, few data have been available to guide the clinical community on the outcomes of AF ablation at ≥3 years of
follow-up. We aimed to systematically review the medical literature to evaluate the long-term outcomes of AF ablation.
Methods and Results-—A structured electronic database search (PubMed, Embase, Web of Science, Cochrane) of the scientiﬁc
literature was performed for studies describing outcomes at ≥3 years after AF ablation, with a mean follow-up of ≥24 months after
the index procedure. The following data were extracted: (1) single-procedure success, (2) multiple-procedure success, and (3)
requirement for repeat procedures. Data were extracted from 19 studies, including 6167 patients undergoing AF ablation. Single-
procedure freedom from atrial arrhythmia at long-term follow-up was 53.1% (95% CI 46.2% to 60.0%) overall, 54.1% (95% CI 44.4%
to 63.4%) in paroxysmal AF, and 41.8% (95% CI 25.2% to 60.5%) in nonparoxysmal AF. Substantial heterogeneity (I2>50%) was
noted for single-procedure outcomes. With multiple procedures, the long-term success rate was 79.8% (95% CI 75.0% to 83.8%)
overall, with signiﬁcant heterogeneity (I2>50%).The average number of procedures per patient was 1.51 (95% CI 1.36 to 1.67).
Conclusions-—Catheter ablation is an effective and durable long-term therapeutic strategy for some AF patients. Although
signiﬁcant heterogeneity is seen with single procedures, long-term freedom from atrial arrhythmia can be achieved in some
patients, but multiple procedures may be required. ( J Am Heart Assoc. 2013;2:e004549 doi: 10.1161/JAHA.112.004549)
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C atheter ablation of atrial ﬁbrillation (AF) has become anestablished therapeutic modality for the treatment of
patients with symptomatic AF.1 To date, studies reporting
outcomes of AF ablation have predominantly limited follow-up
to 1 to 2 years after the index ablation procedure.2–4
Although the long-term efﬁcacy of AF ablation is less precisely
deﬁned, it is of critical relevance to individual patient
prognosis, clinical decision making, and reimbursement
policies for the procedure. Until recently, few series have
presented the long-term outcomes of AF ablation at ≥3 years
of follow-up. In the current study, we systematically reviewed
the medical literature to evaluate the long-term single- and
multiple-procedure efﬁcacy of AF ablation.
Methods
The study was conducted in accordance with principles estab-
lished for meta-analyses of observational studies.5 We searched
PubMed, Embase, Web of Science, and Cochrane Database for
published articles describing long-term outcomes in patients
undergoing catheter ablation of AF. The search design was
conducted with the assistance of a research librarian, and the
detailed search methodology is presented in Appendix S1. This
search was supplemented by hand-searching bibliographies of
published studies and relevant review articles. Citations were
included if they involved an evaluation of percutaneous catheter
ablation outcomes at ≥3 years after the index ablation proce-
dure, with a mean/median follow-up of ≥24 months. Random-
ized controlled trials, case–control studies, cohort studies, and
case series were included. Individual case reports, editorials,
review articles, and meeting abstracts were excluded. Studies
published in languagesother thanEnglishwereexcluded. Studies
involving surgical AF ablation and AV nodal ablation, or exclusive
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right atrial ablation, were excluded. The searchwas conductedon
July 8, 2011. Citations were appraised by 3 independent
reviewers (A.G., N.J.S., A.G.B.), with differences resolved by
consensus. Selected publicationswere analyzed for the following
outcomes: (1) primary ablation success—deﬁned as cumulative
survival free of recurrent atrial arrhythmia; (2)multiple-procedure
success—deﬁned as cumulative survival free of atrial arrhyth-
mia, including patients receiving >1 ablation procedure; and (3)
number of patients undergoingmultiple procedures.We included
data presented asKaplan–Meier analyses or actuarial recurrence
rates. Latest follow-up was deﬁned as the latest follow-up time
point with ≥30 patients at risk. The deﬁnitions of postprocedure
blanking period and use of antiarrhythmic drugs were left to
individual study design. If on-drug and drug-free success data
were available, drug-free success data were included in the
statistical analysis. Study data were clariﬁed with original
investigators if required. Study quality was assessed using a
modiﬁed version of quality assessment criteria for case series.6
Statistical Analysis
Cumulative survival data were obtained from each study and
pooled at the 1-year follow-up and latest follow-up time points.
For Kaplan–Meier data, arrhythmia-free survival rates were
extracted using graphic digitization software (DigitizeIt). In the
absence of standard errors for each Kaplan–Meier curve, the
number at risk at the time point of interest was used to
conservatively estimate the standard error. A pooled estimate
of survival at 12months and the latest follow-upwas calculated,
using random-effects models based on logit transformed
proportions.7 The time point of latest follow-up in a study was
deﬁned as the last time point reporting a minimum of 30
subjects at risk. A minimum of 3 studies was required to
perform meta-analysis. Heterogeneity was assessed with the
I2 statistic, with 50% deﬁned as the threshold for signiﬁcant
heterogeneity.8 Subgroup analysis and random-effects meta-
regression were performed to explore possible reasons for
heterogeneity of study outcomes. Evidence for publication bias
was assessed graphically using funnel plots. For the number of
procedures per patient, exact Poisson CIs were calculated
around each study estimate. Study estimates and CIs were then
pooled using random-effects models. Statistical analysis was
performed with Comprehensive Meta-Analysis software, ver-
sion 2 (Biostat) and STATA version 11 (StataCorp).
Results
Search and Synthesis of Literature
We identiﬁed 2589 unique citations after the initial literature
search was combined with supplementary hand searches;
2090 were excluded after screening of abstracts and titles,
and 480 were selected for detailed secondary review of the full
text and/or abstract. A total of 19 publications were identiﬁed
that met the inclusion criteria (Figure 1).9–27 Baseline charac-
teristics of these 19 studies are presented in Table 1. Included
studies were published in 2003–2011, with study enrolment
from 1998 to 2009. The included studies consisted of 15
single-center case series, 2 multicenter case series, and 2
randomized controlled trials. Prospective recruitment occurred
in 7 studies,13–15,17,18,24,25 with 12 studies recruiting retro-
spectively.9–12,16,19,21–23,26,27 Study size varied considerably,
from small (Katritsis et al, N=39 patients)13 tomuch larger studies
(Bhargava et al, N=1404 patients.17 Eleven studies reported
outcome data for paroxysmal AF (PAF) patients.11,13–18,20–22,25
Six studies reported data for nonparoxysmal AF (NPAF)
patients.15,17,18,25–27 Six studies provided overall outcome
data for mixed PAF/NPAF cohorts.9,10,12,19,24,25
Study quality was assessed using a modiﬁed version of
quality assessment criteria for case series.6 Study quality was
generally limited, with the majority of studies having identi-
ﬁable limitations in study design (Appendix S2). Patient entry
criteria were generally well deﬁned. However, important
features, such as study design including consecutive recruit-
ment, losses to follow-up, and prognostic factors for recur-
rence or ablation success, were only variably reported.
Baseline Patient Characteristics
A total of 6167 patients were included from the 19 studies.
The mean age of patients in the included studies ranged from
51 to 65 years (Table 1). All studies predominantly included
male subjects, with the proportion of male subjects varying
from 57% to 90% (Table 1).The mean left atrial diameter
varied from 38 to 47 mm and the mean left ventricular
ejection fraction varied from 53% to 70% (Table 1).
Catheter Ablation Approach
Pulmonary vein (PV) isolation using radiofrequency energy
was the method of ablation in the majority of included studies
(Table 2). A wide area or PV antral circumferential ablation
strategy was used in 10 studies.11,14,15,17,18,20–22,25,27 Seg-
mental PV isolation was used in 4 studies.11,13,14,23 The
stepwise ablation technique was the procedure of choice in 2
studies.24,26 Two studies used an anatomical electroanatomic
map-guided ablation approach without PV isolation as an end
point.9,10 One study reported outcomes after selective
ablation of arrhythmogenic veins deﬁned by ectopic ﬁring in
the baseline state or presence of isoproterenol.19 The 2
randomized controlled trials reported comparisons of ablation
strategies.14,15 Early studies tended to use nonirrigated
conventional ablation catheters, with later published studies
using predominantly irrigated ablation catheters.
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Follow-up
The mean or median duration of follow-up in included studies
varied from 28 to 71 months (Table 2). Follow-up intensity
differed between studies. The majority of studies (13/15)
conducted a clinic visit with ≥24-hour Holter monitoring and
electrocardiography on ≥4 occasions in the ﬁrst year after
index ablation. After the ﬁrst year, follow-up intensity was
generally reduced in most studies (Table 2). Although some
studies continued at least 3 to 6 monthly clinic visit and
Holter monitoring, other studies reported outcome results
beyond 1 year based on data from referring clinicians or
direct contact by research personnel with patients. One
study rehospitalized patients at 5 year for inpatient Holter,
electrocardiographic, and exercise stress testing.24 One
study assessed AF recurrence based on a prospective AF
registry.25
Single-Procedure Efﬁcacy of Catheter Ablation
Outcome data regarding the efﬁcacy of catheter ablation of
AF were available in all studies. Most studies provided single-
procedure success rates, deﬁned as the percentage of
patients free of atrial arrhythmia or not requiring a second
procedure at 12 months. The pooled overall success rate was
64.2% (95% CI 57.5% to 70.3%, Figure 2A). The pooled 12-
month success rate for the 11 studies reporting outcomes for
PAF patients was 66.6% (95% CI 58.2% to 74.2%, Figure 2A),
and for the 6 studies reporting outcomes for NPAF patients, it
was 51.9% (95% CI 33.8% to 69.5%, Figure 2A). Heterogeneity
exceeded 50% in each of these groups. At late follow-up, the
overall single-procedure success, deﬁned as freedom from
atrial arrhythmia at latest follow-up, was 53.1% (95% CI 46.2%
to 60.0%, Figure 2B). Mean long-term success in the studies
separately reporting PAF outcome was 54.1% (95% CI 44.4%
Figure 1. Search criteria and ﬂow diagram for studies included in this systematic review. AF indicates atrial ﬁbrillation; SVT, supraventricular
tachycardia; AV, atrioventricular; CRT, cardiac resynchronization therapy; RA, right atrial.
DOI: 10.1161/JAHA.112.004549 Journal of the American Heart Association 4
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to 63.4%, Figure 2B), and in the 4 studies reporting NPAF
outcome, it was 41.8% (95% CI 25.2% to 60.5%, P=0.3 versus
PAF, Figure 2B). I2 exceeded 50% for long-term single-
procedure outcome data, indicating signiﬁcant heterogeneity
(Figure 2B). Long-term single-procedure outcomes for long-
standing persistent AF were reported in 3 studies,17,23,27 but
meta-analysis was not performed due to small numbers (<10
patients) of patients at late-term follow-up in 2 of these
studies.23,27
We speciﬁcally evaluated the impact of segmental com-
pared with circumferential PV isolation. There was no
statistical difference in outcomes for segmental PV isolation
(5 studies, 52.4% [95% CI 30.2% to 73.8%]) compared with
wide antral circumferential PV isolation 51.6% (9 studies, 95%
CI 42.7% to 60.4%, P=0.947).
We also speciﬁcally analyzed the impact of antiarrhythmic
drugs by assessing late single-procedure outcomes in the
subgroup of 14 studies reporting drug-free success. In this
group, late single-procedure success was 57.4% (95% CI
50.9% to 63.8%), which was similar to overall clinical
outcomes.
Impact of Multiple Procedures
Thirteen studies provided outcome data taking into consider-
ation the impact of multiple procedures. The overall multiple-
procedure long-term success rate was 79.8% (95% CI 75.0% to
83.8%) in 13 studies (Figure 3). The I2 overall was >50%,
indicating signiﬁcant heterogeneity. The multiple-procedure
long-term success in PAF was 79.0% in 8 studies (95% CI
67.6% to 87.1%, Figure 3), and that in NPAF was 77.8% in 4
studies (95% CI 68.7% to 84.9%, P=0.9 versus PAF, Figure 3).
In the individual groups, heterogeneity exceeded 50%. The
overall average number of procedures was 1.51 (95% CI 1.36
to 1.67). In PAF patients, the average number of procedures
was 1.45 (95% CI 1.31 to 1.59) compared with 1.67 (95% CI
1.31 to 2.06) in NPAF patients (P=0.2).
Late Recurrence After AF Ablation
To evaluate the timing of late recurrence, pooled estimates of
single- and multiple-procedure arrhythmia-free success were
evaluated for the subset of studies providing yearly follow-up
data at up to 5 years from index ablation (Figure 4). After a
single procedure, the 1-year success rate in these studies was
65.3% (95% CI 57.5% to 72.4%), which decreased to 56.4%
(95% CI 47.9% to 64.5%) at 3 years and stabilized at 51.2%
(95% CI 37.3% to 65.0%) at 5 years (Figure 4A). For multiple-
procedure success, the 1-year success rate was 85.7% (95%
CI 81.9% to 88.7%), which decreased to 79.3% (95% CI 76.3%
to 82.0%) at 3 years and 77.8% (95% CI 70.3% to 83.8%) at
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Paroxysmal AF 
66.6% (95% CI: 58.2%-74.2%) 
I2= 89.4%
Non-paroxysmal AF 
51.9% (95% CI: 33.8%-69.5%) 
I2=94.4%
Overall success
64.2% (95% CI: 57.5%-70.3%) I2=
93.6%
Fiala 2008 a – segmental pulmonary vein isolation arm; Fiala 2008 b 
Electroanatomic map guided ablation; Gaita 2009 a pulmonary vein 
isolation; Gaita 2009 b pulmonary vein isolation plus linear ablation.P = 
paroxysmal AF results for study. N= nonparoxysmal AF results for study. 
Single procedure success data for Shah et al., Bertaglia et al, and Tzou et al., 





41.8% (95% CI: 25.2-60.5%)
I2= 83.7%
Overall success
53.1% (95% CI: 46.2-60.0%)
I2= 87.6%
Fiala 2008 a – segmental pulmonary vein isolation arm; Fiala 2008 b 
Electroanatomic map guided ablation; Gaita 2009 a pulmonary vein isolation; 
Gaita 2009 b pulmonary vein isolation plus linear ablation.P = paroxysmal AF 
results for study. N= nonparoxysmal AF results for study. Single procedure 
success data for Shah et al., Bertaglia et al, and Tzou et al., were recalculated 
against original cohort size.
A
B
Figure 2. Single-procedure success at 12 months postprocedure (A) and at late follow-up (B). AF indicates atrial ﬁbrillation.
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When grouped by AF type, single-procedure success data
were available from 16 studies for 1 to 3 years, 7 studies at
4 years, and 4 studies at 5 years. For PAF, single-procedure
success was 68.6% (95% CI 58.9% to 77.0%) at 1 year, 61.1%
(95% CI 49.8% to 71.2%) at 3 years, and 62.3% (95% CI 39.8%
to 80.5%) at 5 years (Figure 4B). For NPAF, single-procedure
success was 50.8% (95% CI 34.3% to 67.2%) at 1 year and
41.6% (95% CI 24.7% to 60.8%) at 3 years. Meta-analysis was
not performed after 3 years because <3 studies were present
beyond this time point.
Predictors of Recurrent Arrhythmia
We evaluated predictors of success using meta-regression to
explore study-level covariates responsible for between-study
heterogeneity. We modeled the late single-procedure success
and multiple-procedure success considering mean age, left
atrial size, sex, and proportion of PAF as study-level
covariates. None of the study-level covariates was predictive
of single-procedure or multiple-procedure success. Thirteen
individual studies reported predictors of recurrence in AF
ablation in univariate and/or multivariate analysis (Table 3).
Commonly identiﬁed variables predictive of AF recurrence
included NPAF, left ventricular systolic dysfunction or heart
failure, structural or valvular heart disease, and duration
of AF.
Mechanisms of Recurrence
Mechanisms of recurrence were reported in 5 studies.16,17,19,21,22
In these 5 studies, 3 of which reported data exclusively from PAF
patients, PV reconnection was noted in 417 of 423 patients who
underwent repeat ablation; the rate of ≥1 PV reconnection was
97.2% (95% CI 92.7% to 99.0%). Insufﬁcient data were available in
these studies to report on the proportion of PVs undergoing
reconnection or to permit stratiﬁcation of reconnection rates
based on type of AF or ablation strategy or technology.
Periprocedural Complications
Periprocedural complications were reported heterogeneously
across studies. Reported complications are shown in Table 4.
Serious complications noted in the studies included cerebro-
vascular accident, PV stenosis, atrioesophageal ﬁstula, and
cardiac tamponade. Overall rates of serious complications
appeared to be low (Table 4).
Publication Bias
To evaluate the included studies for publication bias, we
constructed funnel plots for 12-month success, late success,
and multiple-procedure late success (Appendix). There was
some suggestion of an association between the log odds of
Paroxysmal AF
79.0% (95% CI: 67.6%-87.1%)
I2= 89.8%
Non-paroxysmal AF
77.8% (95% CI: 68.7-84.9%)
I2= 71.9%
Overall success
79.8% (95% CI: 75.0-83.8%)
I2= 83.9%
Fiala 2008 a – segmental pulmonary vein isolation arm; Fiala 2008 b 
Electroanatomic map guided ablation; Gaita 2009 a pulmonary vein 
isolation; Gaita 2009 b pulmonary vein isolation plus linear ablation.P = 
paroxysmal AF results for study. N= nonparoxysmal AF results for study
Figure 3. Multiple late procedure success, deﬁned as the cumulative arrhythmia-free survival at ≥3 years. AF indicates atrial ﬁbrillation.
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success and the standard error of the log odds, particularly for
late success, with larger, more precise studies tending to
report higher success rates.
Discussion
In this systematic review, we found that AF ablation may
lead to long-term freedom from atrial arrhythmia that is
maintained at follow-up of ≥3 years. The principal ﬁndings
were that (1) a single ablation procedure may be sufﬁcient to
achieve freedom from atrial arrhythmia in 50% of patients,
although substantial heterogeneity was noted (I2≥50%);
(2) multiple procedures will be required to achieve control
of AF in many patients, but 80% of patients will achieve
long-term freedom from atrial arrhythmia; and (3) although
there is an incidence of late recurrence in initially successfully
ablated patients, there is relative stability of arrhythmia-free
survival at late-term follow-up of 5 years.
Long-term Ablation Efﬁcacy
Until very recently, few data have been available on AF
ablation outcomes beyond 3 years after the index procedure.
Indeed, current guidelines deﬁne “very late” recurrence as
atrial arrhythmia >1 year after ablation and recommend
follow-up until 2 years.2 In our study, we addressed the issue
of AF ablation outcomes at ≥3 years of follow-up. We used
drug-free success data, where available, and follow-up
intensity was determined by individual study design. A
particular consideration in a study such as this one is that
the studies were reports generated at highly experienced
referral centers with considerable experience in the applica-
tion of AF abation. Ablation procedures were performed by
experienced operators in selected AF patients. An interesting
observation in our study was that the funnel plots of
procedure outcomes in larger studies tended to have higher
rates of success, perhaps reﬂecting an experience effect.
However, an alternative interpretation raised by these data is
that of ascertainment bias, with the possibility that different
results would be achieved for procedures undertaken in lower-
volume, less-experienced clinical centers.
Single-procedure ablation success was achieved in 50%
of patients, although, importantly, there was signiﬁcant
heterogeneity in single-procedure outcomes in the included
studies. With the inclusion of multiple procedures, 80% of
patients achieved long-term freedom from atrial arrhythmia.
To evaluate the long-term stability of AF ablation success,
we evaluated the annualized arrhythmia-free success of AF
ablation from 1 to 5 years. Both single- and multiple-procedure
success rates showed relative stability at >3 years after index
ablation. Including multiple procedures, 80% of patients in
the included studies were free of atrial arrhythmia at long-term
follow-up. These data combined suggest that medium-term
ablation success appears to portend relative stability of long-
term efﬁcacy of AF ablation but with a signiﬁcant residual risk
of recurrence affecting a signiﬁcant minority of patients.
Impact of Type of AF
The results of our study conﬁrm previous data on the
importance of AF classiﬁcation to outcomes after AF ablation.
Years After 
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A
B
Figure 4. A, Annualized single- and multiple- procedure arrhythmia-
free success were calculated (subtable number of studies at each
year after ablation). B, Annualized PAF and NPAF single-procedure
arrhythmia-free success were calculated (subtable number of studies
at each year after ablation). Meta-analysis for NPAF was not
performed beyond 4 years, because only 2 studies reported at this
duration of follow-up. PAF indicates paroxysmal atrial ﬁbrillation;
NPAF, nonparoxysmal atrial ﬁbrillation.
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The PAF ablation cohort had superior single-procedure
success compared with NPAF patients. A minority of NPAF
patients in the current study achieved rhythm control with a
single procedure, with long-term rhythm control typically
requiring multiple procedures. In our study, NPAF single-
procedure outcomes were surprisingly statistically not differ-
ent compared with PAF outcomes. It appears that this
unexpected ﬁnding is related to the substantial between-study
heterogeneity of procedural outcomes in both PAF and NPAF
cohorts, as NPAF outcomes were signiﬁcantly worse than
those for PAF patients in all studies reporting success data for
both types of patients. It should also be emphasized that long-
term outcome data for NPAF patients that were available were
derived from a subset of included studies. Importantly, 80%
of PAF and NPAF patients achieved durable sinus rhythm
control at long-term follow-up, with the inclusion of multiple
procedures. Few studies reported long-term outcomes beyond
3 years in NPAF patients, suggesting that further data may be
required to deﬁnitively assess the long-term efﬁcacy of
ablation in this group.
Mechanisms of Recurrence
The mechanism of recurrence in included studies was
overwhelmingly related to PV reconnection, derived from
the subset of studies reporting procedural data on this
outcome. High rates of PV reconnection appear to occur in
both PAF and NPAF patients. This would suggest that
improvement in overall outcomes of the procedure may
require improvements in both technique and technology. The
extent of data available did not allow identiﬁcation of other
factors that may contribute to recurrence in these studies.
Nevertheless, a number of studies have demonstrated the
importance of patient substrate factors including type of AF,
left atrial diameter, structural heart disease, left ventricular
dysfunction, hypertension, obesity, and obstructive sleep
apnea.28–31
Clinical Parameters Related to Between-Study
Heterogeneity
In the current study, substantial heterogeneity was observed
in single-procedure outcome (Figure 2), with a signiﬁcant risk
of late recurrence after index ablation (Figure 4A). The wide
disparity in reported success rates between the included
studies is in itself an outcome of signiﬁcant importance. We
explored possible reasons for recurrence with a meta-
regression analysis using age, sex, percentage of PAF
patients, left atrial diameter, and mean left ventricular
ejection fraction as moderator variables. None of the study
variables was found to be statistically predictive of short- or
late-term success outcomes after AF ablation. At the study
level, a wide array of covariates were found to be associated
with ablation outcomes (Table 3), suggesting that further
information is required to precisely predict factors related to
prognosis in individual patients.
Table 3. Risk Factors for Recurrence or Success After AF Ablation Were Presented for 13 Studies
Study Predictive Model Covariates Predictive of Reurrence/Success
Pappone, 20039 Cox proportional hazards LA diameter >45 mm predicted recurrence
Pratola, 200810 Cochran-Mantel-Haenzel statistic Age, presence of recurrent AF in 2 to 6 mo after ablation predicted recurrence
Sartini, 200811 Cox proportional hazards Age, time of AF, number of drugs and associated ﬂutter, delivery power predicted recurrence
Shah, 200812 Cox proportional hazards Hypertension, hyperlipidemia predicted recurrence
Sawhney, 200916 Cox proportional hazards Hypertension predicted recurrence
Bhargava, 200917 Cox proportional hazards NPAF predicted recurrence
Bertgalia, 201018 Cox proportional hazards No variables identiﬁed predictive of recurrence
Tzou, 201019 Cox proportional hazards PAF, smaller LA size, fewer AF triggers, fewer PVs isolated predicted success
Hunter, 201020 Cox proportional hazards Structural heart disease, persistent AF, and female sex predicted recurrence
Weerasooriya, 201124 Cox proportional hazards Long-standing persistent AF, valvular heart disease, nonischemic dilated cardiomyopathy
predicted recurrence
Hussein, 201125 Cox proportional hazards Male, older age, higher BMI, NPAF, hypertension, lower LVEF, hsCRP, BNP predictive of early
recurrenceAge, NPAF, left atrial size predicted late recurrence
Rostock, 201126 Cox proportional hazards Male sex, duration of persistent AF >6 mo, congestive heart failure, shorter AFCL predicted
recurrenceAF termination predicted success
Winkle, 201127 Cox proportional hazards Age, left atrial size, female sex, long-standing persistent AF, persistent AF, presence of CAD,
predicted recurrence
AF indicates atrial ﬁbrillation; LA, left atrial; NPAF, nonparoxysmal AF; PAF, paroxysmal AF; PV, pulmonary vein; BMI, body mass index; LVEF, left ventricular ejection fraction; hsCRP, high
sensitivity C-reactive protein; BNP, B-type natriuretic peptide; AFCL, atrial ﬁbrillation cycle length; CAD, coronary artery disease.
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Although we were not able to provide a statistical
explanation for between-study heterogeneity, we suggest that
several areas of clinical difference between studies may
account for differences in outcomes: (1) differences in patient
population receiving ablation, (2) differences in technique and
technology used during ablation, (3) differences in the use and
reporting of antiarrhythmic drug therapy after ablation, (4)
follow-up frequency and intensity, (5) deﬁnitions of procedural
success or failure, and (6) differences in the availability and
timing of repeat procedures. Standardization of reporting of
these clinical parameters is an area that may need to be
addressed in future revisions to current clinical guidelines. An
area that may require particular emphasis is the need for long-
term follow-up of AF ablation patients, which we believe may
need to be extended beyond the 12-month window postpro-
cedure recommended in current clinical guidelines.2
Comparisons to Previous Meta-analyses
Over the years, a number of studies have addressed the
shorter-term outcomes,32–34 predictors of recurrence,28,29 or
impact of speciﬁc types of ablation strategy.35,36 The current
study, for the ﬁrst time, addresses the signiﬁcant clinical issue
of the long-term clinical outcomes of AF ablation, which has
only recently become possible due to the availability of long-
term clinical follow-up data after AF ablation.
Clinical Implications
The long-term results of AF ablation are critically important not
only for individual patient prognosis and clinical decisionmaking
but also for determining the role of reimbursement policy for the
procedure. The data presented in the current study suggest that
long-term freedom of atrial arrhythmia can be achieved in the
majority of AF cases, taking into account the need for multiple
procedures in a signiﬁcant proportion of patients.
Study Limitations
The results of this report were compiled using meta-analyses of
primarily nonrandomized observational data, rather than
randomized controlled trial data, with signiﬁcant limitations
in study quality, thereby having some risk of bias.5,37 The
technique of meta-analysis was originally developed for
prospectively conducted randomized controlled trials, which
represent the highest quality of evidence evaluating the
efﬁcacy of clinical interventions. In recent years, however,
meta-analysis has become accepted in the literature to
aggregate results from observational data, to facilitate synthe-
sis of available evidence and generation of new hypothe-
ses.37,38 In the case of AF ablation, the procedure is relatively
new, with signiﬁcant ongoing innovation in technology and
Table 4. Complications of Catheter Ablation in the Included
Studies
Study N Complications
Pappone, 20039 589 Not reported
Pratola, 200810 72 1 hematoma, 1 cardiac tamponade,
1 acute myocardial infarction
Sartini, 200811 139 1 transient ischemic attack, 1 acute
myocardial infarction, 1
atrioesophageal ﬁstula causing
death, 5 cardiac tamphonade, 1
deep venous thrombosis
Shah, 200812 264 Not reported
Katritisis, 200813 39 1 cardiac tamponade
Fiala, 200814 110 1 pseudoaneurysm, 1 stroke
Gaita, 200815 204 2 transient ischemic attacks, 1
pseudoaneurysm, 1 esophageal
ulceration
Sawhney, 200916 71 1 femoral hematoma, 2
pseudoaneurysms




Bertgalia, 201018 177 Not reported
Tzou, 201019 123 Not reported
Hunter, 201020 285 3 cerebrovascular events, 9 cardiac
tamponades, 3 pulmonary vein
stenoses, 77 groin hematomas,
1 pseudoaneurysm
Ouyang, 201021 177 1 noninfectious pericarditis,
1 asymptomatic pulmonary
vein stenosis
Medi, 201122 100 No complications





100 3 cardiac tamponades, 3 pericardial
effusions, 1 asymptomatic
pulmonary vein stenosis, 1
pseudoaneurysm, 1 anaphylaxis,
1 ventricular ﬁbrillation secondary
to direct current cardioversion
Hussein, 201125 831 1 arteriovenous ﬁstula, 1 cardiac
tamponade, 3 cerebrovascular
events, 3 groin hematomas, 6
asymptomatic pulmonary vein
stenoses
Rostock, 201126 395 3 left atrial appendage isolations,
6 pacemaker implants due to
sinus arrest, 4 cardiac
tamponades, 1 transient
ischaemic attack
Winkle, 201127 893 3 strokes, 1 pulmonary vein stenosis;
other complications not speciﬁed
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technique, necessitating the inclusion of case series as well as
randomized controlled trial data. In addition, the limitation of
included data to published studies may lead to a risk of
publication or “ﬁle drawer” bias, which may favor the
publication of studies showing an improvement in outcomes.39
Signiﬁcant heterogeneity was identiﬁed, although lack of
similarity in reporting of outcome and moderator variables
limited the opportunity for more detailed subgroup analyses.
However, we speciﬁcally acknowledge the limitations and
inherent bias that may occur with this approach. A further
limitation of our study is that periprocedural complications, a
critical consideration in evaluating the risks and beneﬁts of the
procedure, were variably reported in terms of level of detail,
and in some studies not reported at all. The conclusions of our
study are therefore predicated on explicit acknowledgment of
these possible limitations in the study design.
Conclusions
The data presented in this review showed encouraging rates
of success at long-term follow-up after early experience with
catheter ablation of AF. Although single-procedure outcomes
were associated with signiﬁcant heterogeneity, with the
inclusion of multiple procedures, long-term freedom from
atrial arrhythmia was achievable in the majority of patients.
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Appendix 1: Search Strategy for Long Term Outcomes Systematic 
Review 
 
Patient population: patients with atrial fibrillation, undergoing catheter ablation 
 
Intervention of interest: percutaneous catheter ablation 
 
Outcomes: studies reporting outcomes (in terms of recurrence of AF/ or ablation 
success) at greater than or equal to 3 years following the index procedure. 
 
 




 relaps*[tw] long term[tw] 
atrium fibril*[tw]  recrudescen*[tw] time 
factor*[tw] 
  reoccurren*[tw] Cohort 
analysis[tw] 
  treatment outcome[mh]  
  outcome*[tw]  
  treatment failure*[tw]  
  success*[tw]  




 (atrial fibril*[tw] OR auricular fibril*[tw] OR atrium fibril*[tw]) AND (catheter ablation 
[mh] OR ablation*[tw]) AND (recurren*[tw] OR relaps*[tw] OR recrudescen*[tw] OR 
reoccurren*[tw] OR treatment outcome[mh] OR outcome*[tw] OR treatment 
failure*[tw] OR success*[tw] OR disease free[tw]) AND (Cohort studies [mh] OR long 
term[tw] OR time factor*[tw] OR cohort analysis[tw]) 
 
Embase 
 ('heart atrium fibrillation':de OR 'atrium fibrillation':ab,ti OR 'atrium fibrilation':ab,ti OR 
'atrial fibrillation':ab,ti OR 'atrial fibrilation':ab,ti OR 'auricular fibrillation':ab,ti OR 
'auricular fibrilation':ab,ti) AND ('catheter ablation':de OR ablation*:ab,ti) AND 
('recurrent disease':de,ab,ti OR recurren*:ti,ab OR relaps*:ab,ti OR 
recrudescen*:ab,ti OR reoccurren*:ab,ti OR 'treatment outcome'/exp OR 
outcome*:ab,ti OR 'treatment failure':de,ab,ti OR 'treatment failures':ab,ti OR 
success*:ab,ti OR 'disease free':ab,ti) AND (time/exp OR time:ab,ti OR 'long 
term':ab,ti OR 'cohort analysis':de,ab,ti OR 'cohort study':ab,ti OR 'cohort 
studies':ab,ti) 
  
Web of Knowledge 
(('atrium fibril*' OR 'atrial fibril*' OR 'auricular fibril*') AND ('catheter ablation*' OR 
'electrical ablation' OR 'electric ablation') AND (recurren* OR relaps* OR 
recrudescen* OR reoccurren* OR outcome* OR 'treatment failure*' OR success* OR 




(fibrillation NEXT ablation OR fibrilation NEXT ablation OR (atrium NEXT fibrillation 
OR atrium NEXT fibrilation OR atrial NEXT fibrillation OR atrial NEXT fibrilation OR 
auricular NEXT fibrillation OR auricular NEXT fibrilation) AND (catheter NEXT 
ablation OR catheter NEXT ablations OR electrical NEXT ablation OR electric NEXT 
ablation)) AND (recurren* OR relaps* OR recrudescen* OR reoccurren* outcome* 
OR treatment NEXT failure OR success* OR disease NEXT free) AND (time OR 
long NEXT term) 
















No Loss to 
follow-up 













   Not 
reported 
   
Pratola 200810        
Sartini 200811    Not 
reported 
   




   
Katritsis 
200813 
       
Fiala 200814       RCT 
Gaita 200815    Not 
reported 
  RCT 
Sawhney 
200916 
   Not 
reported 
   
Bhargava 
200917 
   Not 
reported 
   
Bertaglia 
201018 
   Not 
reported 
   
Tzou 201019        
Hunter 201020        
Ouyang 
201021 
   Not 
reported 
   
Medi 201122    Not 
reported 
   
Matsuo 201123    Not    




       
Hussein 
201125 
       
Rostock 
201126 
   Not 
reported 
   
Winkle 201127        
 
*RCT=randomizedcontrolled trial
Appendix 3 Mechanisms of Recurrence 
Sawhney 2009 
 
31/31 cases with repeat ablation had 
recovery of PV-LA conduction 
Bhargava 2009* 
 
100% of repeat procedures has recovery 
of PV-LA conduction 
Ouyang 2010 90% recovery of PV-LA conduction 
Tzou 2010 
 
96% recovery of PV-LA conduction. 
Medi 2011 
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